Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.72) by ($0.31), Briefing.com reports. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The firm had revenue of $108.83 million during the quarter, compared to analysts' expectations of $116.03 million. During the same period in the prior year, the company posted ($2.33) EPS. The company's revenue for the quarter was up 8.3% compared to the same quarter last year.

Ultragenyx Pharmaceutical Stock Down 1.0 %

NASDAQ RARE traded down $0.45 during trading hours on Friday, hitting $42.75. 1,143,007 shares of the company were exchanged, compared to its average volume of 767,975. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -5.34 and a beta of 0.68. The company has a 50 day moving average of $47.38 and a two-hundred day moving average of $44.04. Ultragenyx Pharmaceutical has a 52-week low of $31.52 and a 52-week high of $54.98.

Insider Activity

In related news, Director Matthew K. Fust sold 12,195 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $50.88, for a total transaction of $620,481.60. Following the sale, the director now directly owns 14,860 shares in the company, valued at $756,076.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider John Richard Pinion sold 4,173 shares of the company's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $224,340.48. Following the completion of the transaction, the insider now directly owns 89,268 shares of the company's stock, valued at approximately $4,799,047.68. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Matthew K. Fust sold 12,195 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $50.88, for a total value of $620,481.60. Following the completion of the transaction, the director now owns 14,860 shares in the company, valued at approximately $756,076.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,116 shares of company stock worth $1,645,983. 6.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Robert W. Baird upped their price objective on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a report on Tuesday, January 30th. JPMorgan Chase & Co. increased their price target on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an "overweight" rating in a report on Monday, March 18th. Cantor Fitzgerald restated an "overweight" rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday. Royal Bank of Canada started coverage on shares of Ultragenyx Pharmaceutical in a research note on Monday, April 22nd. They set an "outperform" rating and a $77.00 target price for the company. Finally, Wedbush reduced their price target on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $88.00.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.